BioBrief closes the week with a selective but constructive biotech tape, where strategic buyers and public investors continued rewarding commercial traction, differentiated specialty assets, and credible pipeline expansion.

In today’s BioBrief:

• Bayer / Perfuse Therapeutics — Bayer agreed to acquire Perfuse for $300 million upfront and up to $2.45 billion total, adding the Phase 2 ophthalmology asset PER-001 for glaucoma and diabetic retinopathy.
• TG Therapeutics / Briumvi — TG continued to benefit from strong first-quarter Briumvi sales in relapsing multiple sclerosis, after reporting nearly $195 million in U.S. revenue and raising full-year guidance to roughly $885–900 million.
• Madrigal / Arrowhead / ARO-PNPLA3 — Madrigal expanded beyond Rezdiffra ...